How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

World Journal of Gastroenterology

Volumn 19, Issue 45, 2013, Pages 8168-8180

  Ierardi, Enzo ^a   Giorgio, Floriana ^a   Losurdo, Giuseppe ^a   Di Leo, Alfredo ^a   Principi, Mariabeatrice ^a  

^a Section of Gastroenterology   (Italy)

Author keywords

Antibiotic resistance; Geography; Helicobacter pylori; Therapeutic outcome; Therapeutic regimens

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CIPROFLOXACIN; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; DISEASE ERADICATION; ERADICATION THERAPY; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; POINT MUTATION; PREVALENCE; TREATMENT OUTCOME;

ANTIBIOTIC RESISTANCE; GEOGRAPHY; HELICOBACTER PYLORI; THERAPEUTIC OUTCOME; THERAPEUTIC REGIMENS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; GEOGRAPHY, MEDICAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PHENOTYPE; PREVALENCE; PROBIOTICS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84889572012     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i45.8168     Document Type: Article

References (173)

1. Dore MP, Fanciulli G, Tomasi PA, Realdi G, Delitala G, Graham DY, Malaty HM. Gastrointestinal symptoms and Helicobacter pylori infection in school-age children residing in Porto Torres, Sardinia, Italy. Helicobacter 2012; 17: 369-373 [PMID: 22967120 DOI: 10.1111/j.1523-5378.2012.00955.x]
2. Bastos J, Peleteiro B, Barros R, Alves L, Severo M, de Fátima Pina M, Pinto H, Carvalho S, Marinho A, Guimarães JT, Azevedo A, La Vecchia C, Barros H, Lunet N. Sociodemographic Determinants of Prevalence and Incidence of Helicobacter pylori Infection in Portuguese Adults. Helicobacter 2013; 18: 413-422 [PMID: 23725608 DOI: 10.1111/hel.12061]
3. Thjodleifsson B, Asbjörnsdottir H, Sigurjonsdottir RB, Gíslason D, Olafsson I, Cook E, Gíslason T, Jogi R, Janson C. Seroprevalence of Helicobacter pylori and cagA antibodies in Iceland, Estonia and Sweden. Scand J Infect Dis 2007; 39: 683-689 [PMID: 17654344]
4. Bakkevold KE. Time trends in incidence of peptic ulcer bleeding and associated risk factors in Norway 1985-2008. Clin Exp Gastroenterol 2010; 3: 71-77 [PMID: 21694849]
5. Bureš J, Kopáčová M, Koupil I, Seifert B, Skodová Fendrichová M, Spirková J, Voříšek V, Rejchrt S, Douda T, Král N, Tachecí I. Significant decrease in prevalence of Helico-bacter pylori in the Czech Republic. World J Gastroenterol 2012; 18: 4412-4418 [PMID: 22969207 DOI: 10.3748/wjg.v18. i32.4412]
6. Svarval' AV, Ferman RS, Zhebrun AB. [Prevalence of Helicobater pylori infection among population of Northwestern federal district of Russian Federation]. Zh Mikrobiol Epidemiol Immunobiol 2011; (4): 84-88 [PMID: 21913398]
7. Patterson T, Straten E, Jimenez S. The prevalence of Helicobacter pylori antibody in different age groups in Central Texas. Clin Lab Sci 2012; 25: 102-106 [PMID: 22693779]
8. Porras C, Nodora J, Sexton R, Ferreccio C, Jimenez S, Dominguez RL, Cook P, Anderson G, Morgan DR, Baker LH, Greenberg ER, Herrero R. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013; 24: 209-215 [PMID: 23263777 DOI: 10.1007/s10552-012-0117-5]
9. Hanafi MI, Mohamed AM. Helicobacter pylori infection: seroprevalence and predictors among healthy individuals in Al Madinah, Saudi Arabia. J Egypt Public Health Assoc 2013; 88: 40-45 [PMID: 23528531 DOI: 10.1097/01. EPX.0000427043.99834.a4]
10. Baik SJ, Yi SY, Park HS, Park BH. Seroprevalence of Helicobacter pylori in female Vietnamese immigrants to Korea. World J Gastroenterol 2012; 18: 517-521 [PMID: 22363117 DOI: 10.3748/wjg.v18.i6.517]
11. Etukudo OM, Ikpeme EE, Ekanem EE. Seroepidemiology of Helicobacter pylori infection among children seen in a tertiary hospital in Uyo, southern Nigeria. Pan Afr Med J 2012; 12: 39 [PMID: 22891097]
12. Benajah DA, Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi SA. Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco). Clin Res Hepatol Gastroenterol 2013; 37: 519-526 [PMID: 23567104 DOI: pii:]
13. Pandeya N, Whiteman DC. Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community. J Gastroenterol Hepatol 2011; 26: 1283-1289 [PMID: 21443663 DOI: 10.1111/j.1440-1746.2011.06726.x]
14. Fawcett JP, Barbezat GO, Poulton R, Milne BJ, Xia HH, Talley NJ. Helicobacter pylori serology in a birth cohort of New Zealanders from age 11 to 26. World J Gastroenterol 2005; 11: 3273-3276 [PMID: 15929181]
15. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 2009; 58: 930-935 [PMID: 19502370 DOI: 10.1099/jmm.0.009993-0]
16. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322 [PMID: 17428887]
17. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384 [PMID: 15306603]
18. Cerqueira L, Fernandes RM, Ferreira RM, Oleastro M, Carneiro F, Brandão C, Pimentel-Nunes P, Dinis-Ribeiro M, Figueiredo C, Keevil CW, Vieira MJ, Azevedo NF. Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens. J Clin Microbiol 2013; 51: 1887-1893 [PMID: 23596234 DOI: 10.1128/JCM.00302-13]
19. Schmitt BH, Regner M, Mangold KA, Thomson RB, Kaul KL. PCR detection of clarithromycin-susceptible and-resistant Helicobacter pylori from formalin-fixed, paraffinembedded gastric biopsies. Mod Pathol 2013; 26: 1222-1227 [PMID: 23579617 DOI: 10.1038/modpathol.2013.48]
20. Rimbara E, Sasatsu M, Graham DY. PCR detection of Helicobacter pylori in clinical samples. Methods Mol Biol 2013; 943: 279-287 [PMID: 23104297 DOI: 10.1007/978-1-60327-353-4_19]
21. Vacher S, Ménard A, Bernard E, Mégraud F. PCR-restriction fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in Campylobacter spp. Antimicrob Agents Chemother 2003; 47: 1125-1128 [PMID: 12604552]
22. Monno R, Giorgio F, Carmine P, Soleo L, Cinquepalmi V, Ierardi E. Helicobacter pylori clarithromycin resistance detected by Etest and TaqMan real-time polymerase chain reaction: a comparative study. APMIS 2012; 120: 712-717 [PMID: 22882260 DOI: 10.1111/j.1600-0463.2012.02896.x]
23. Hao H, Yuan Z, Shen Z, Han J, Sahin O, Liu P, Zhang Q. Mutational and transcriptomic changes involved in the development of macrolide resistance in Campylobacter jejuni. Antimicrob Agents Chemother 2013; 57: 1369-1378 [PMID: 23274667 DOI: 10.1128/AAC.01927-12]
24. Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, Lee MK, Park YS, Lee DH, Jung HC, Song IS. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010; 44: 536-543 [PMID: 20179610 DOI: 10.1097/ MCG.0b013e3181d04592]
25. Matsumura M, Hikiba Y, Ogura K, Togo G, Tsukuda I, Ushikawa K, Shiratori Y, Omata M. Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol 2001; 39: 691-695 [PMID: 11158129]
26. Oleastro M, Ménard A, Santos A, Lamouliatte H, Monteiro L, Barthélémy P, Mégraud F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 2003; 41: 397-402 [PMID: 12517879 DOI: 10.1128/ JCM.41.1.397-402.2003]
27. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E. Clarithromycinresistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100 [PMID: 16418408 DOI: 10.7326/0003-4819-144-2-200601170-00006]
28. Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Ierardi E. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol 2013; 4: 43-46 [PMID: 23946886 DOI: 10.4291/wjgp.v4.i3.43]
29. Barile KA, Silva AL, Xavier JN, Assumpção MB, Corvelo TC. Characterization of 23S rRNA domain V mutations in gastric biopsy patients from the eastern Amazon. Mem Inst Oswaldo Cruz 2010; 105: 314-317 [PMID: 20512246]
30. Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, Nomura H, Satoh K, Hori S, Inoue S, Tomokane T, Kudo M, Inaba T, Take S, Ohkusa T, Yamamoto S, Mizuno S, Kamoshida T, Amagai K, Iwamoto J, Miwa J, Kodama M, Okimoto T, Kato M, Asaka M. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol 2013; 48: 1128-1135 [PMID: 23307042]
31. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009; 14: 86-90 [PMID: 19751432 DOI: 10.1111/j.1523-5378.2009.00714.x]
32. Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int 2010; 52: 187-190 [PMID: 19563459 DOI: 10.1111/j.1442-200X.2009.02915.x]
33. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, Nasu M, Fujioka T. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-4010 [PMID: 17942652]
34. Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013; 18: 274-279 [PMID: 23418857 DOI: 10.1111/hel.12046]
35. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010; 15: 460-466 [PMID: 21083752 DOI: 10.1111/j.1523-5378.2010.00788.x]
36. Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol 2013; 47: 233-238 [PMID: 23090037 DOI: 10.1097/MCG.0b013e3182676e2b]
37. Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 2011; 16: 241-245 [PMID: 21585611 DOI: 10.1111/ j.1523-5378.2011.00841.x]
38. Milani M, Ghotaslou R, Akhi MT, Nahaei MR, Hasani A, Somi MH, Rafeey M, Sharifi Y. The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother 2012; 18: 848-852 [PMID: 22581031 DOI: 10.1007/ s10156-012-0425-4]
39. Rajper S, Khan E, Ahmad Z, Alam SM, Akbar A, Hasan R. Macrolide and fluoroquinolone resistance in Helicobacter pylori isolates: an experience at a tertiary care centre in Pakistan. J Pak Med Assoc 2012; 62: 1140-1144 [PMID: 23866399]
40. Zendedel A, Moradimoghadam F, Almasi V, Zivarifar H. Antibiotic resistance of Helicobacter pylori in Mashhad, Iran. J Pak Med Assoc 2013; 63: 336-339 [PMID: 23914633]
41. Trespalacios AA, Otero W, Caminos JE, Mercado MM, Avila J, Rosero LE, Arévalo A, Poutou-Piñales RA, Graham DY. Phenotypic and genotypic analysis of clarithromycinresistant Helicobacter pylori from Bogotá D.C., Colombia. J Microbiol 2013; 51: 448-452 [PMID: 23990295 DOI: 10.1007/ s12275-013-2465-6]
42. Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr 2013; 56: 645-648 [PMID: 23403439 DOI: 10.1097/MPG.0b013e31828b3669]
43. Salazar CO, Cardenas VM, Reddy RK, Dominguez DC, Snyder LK, Graham DY. Greater than 95% success with 14-day bismuth quadruple anti-Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter 2012; 17: 382-390 [PMID: 22967122 DOI: 10.1111/j.1523-5378.2012.00962.x]
44. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106: 1970-1975 [PMID: 21989146 DOI: 10.1038/ajg.2011.306]
45. Graham DY. Clarithromycin for treatment of Helicobacter pylori infections. Eur J Gastroenterol Hepatol 1995; 7 Suppl 1: S55-S58 [PMID: 8574737]
46. Koivisto TT, Rautelin HI, Voutilainen ME, Niemelä SE, Heikkinen M, Sipponen PI, Färkkilä MA. Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther 2004; 19: 1009-1017 [PMID: 15113368]
47. Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, Talley NJ, Engstrand L, Agréus L. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter 2006; 11: 224-230 [PMID: 16882324]
48. Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova M, Wex T, Tammer I, Schlüter D, Malfertheiner P. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013; 25: 1257-1260 [PMID: 23863261]
49. Larsen AL, Ragnhildstveit E, Moayeri B, Eliassen L, Melby KK. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. APMIS 2013; 121: 353-358 [PMID: 23083455 DOI: 10.1111/apm.12009]
50. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823 [PMID: 11783701]
51. Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2001; 15: 1023-1029 [PMID: 11421878]
52. Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000; 32: 763-768 [PMID: 11215555]
53. Savarino V, Zentilin P, Pivari M, Bisso G, Raffaella Mele M, Bilardi C, Borro P, Dulbecco P, Tessieri L, Mansi C, Borgonovo G, De Salvo L, Vigneri S. The impact of antibiotic resistance on the efficacy of three 7-d regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 893-900 [PMID: 10886045]
54. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59: 783-785 [PMID: 17329269]
55. De Francesco V, Margiotta M, Zullo A, Hassan C, Valle ND, Burattini O, D'Angelo R, Stoppino G, Cea U, Giorgio F, Monno R, Morini S, Panella C, Ierardi E. Claritromycin resistance and Helicobacter pylori genotypes in Italy. J Microbiol 2006; 44: 660-664 [PMID: 17205045]
56. De Francesco V, Giorgio F, Ierardi E, Zotti M, Neri M, Milano A, Varasano V, Luzza F, Suraci E, Marmo R, Marone A, Manta R, Mirante VG, de Matthaeis M, Pedroni A, Manes G, Pallotta S, Usai P, Liggi M, Gatto G, Peri V, Sacco R, Bresci G, Monica F, Hassan C, Zullo A. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointestin Liver Dis 2011; 20: 235-239 [PMID: 21961089]
57. Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical Evaluation of a Ten-Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication of Helicobacter pylori in a High Clarithromycin Resistance Area. Helicobacter 2013; 18: 459-467 [PMID: 23714140 DOI: 10.1111/hel.12062]
58. Molina-Infante J, Gisbert JP. [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. Gastroenterol Hepatol 2013; 36: 375-381 [PMID: 23623461 DOI: 10.1016/ j.gastrohep.2013.02.006]
59. Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes 2013; 4: Epub ahead of print [PMID: 23929066]
60. Oleastro M, Cabral J, Ramalho PM, Lemos PS, Paixão E, Benoliel J, Santos A, Lopes AI. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother 2011; 66: 2308-2311 [PMID: 21764826 DOI: 10.1093/jac/dkr293]
61. Boyanova L, Ilieva J, Gergova G, Spassova Z, Nikolov R, Davidkov L, Evstatiev I, Kamburov V, Katsarov N, Mitov I. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria. J Med Microbiol 2009; 58: 94-100 [PMID: 19074658 DOI: 10.1099/jmm.0.003855-0]
62. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010; 8: 59-70 [PMID: 20014902 DOI: 10.1586/eri.09.113]
63. Karczewska E, Klesiewicz K, Skiba I, Wojtas-Bonior I, Sito E, Czajecki K, Zwolińska-Wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterol Res Pract 2012; 2012: 418010 [PMID: 22693490 DOI: 10.1155/2012/418010]
64. Kupcinskas L, Rasmussen L, Jonaitis L, Kiudelis G, Jørgensen M, Urbonaviciene N, Tamosiunas V, Kupcinskas J, Miciuleviciene J, Kadusevicius E, Berg D, Andersen LP. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. APMIS 2013; 121: 431-436 [PMID: 23078193 DOI: 10.1111/apm.12012]
65. Rerksuppaphol S, Hardikar W, Midolo PD, Ward P. Antimicrobial resistance in Helicobacter pylori isolates from children. J Paediatr Child Health 2003; 39: 332-335 [PMID: 12887661]
66. Grove DI, Koutsouridis G. Increasing resistance of Helicobacter pylori to clarithromycin: is the horse bolting? Pathology 2002; 34: 71-73 [PMID: 11902451]
67. Secka O, Berg DE, Antonio M, Corrah T, Tapgun M, Walton R, Thomas V, Galano JJ, Sancho J, Adegbola RA, Thomas JE. Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. Antimicrob Agents Chemother 2013; 57: 1231-1237 [PMID: 23263004 DOI: 10.1128/AAC.00517-12]
68. Seck A, Burucoa C, Dia D, Mbengue M, Onambele M, Raymond J, Breurec S. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Ann Clin Microbiol Antimicrob 2013; 12: 3 [PMID: 23298145 DOI: 10.1186/1476-0711-12-3]
69. Tanih NF, Ndip RN. Molecular Detection of Antibiotic Resistance in South African Isolates of Helicobacter pylori. Gastroenterol Res Pract 2013; 2013: 259457 [PMID: 23710166 DOI: 10.1155/2013/259457]
70. Edwards DI. Mechanism of antimicrobial action of metronidazole. J Antimicrob Chemother 1979; 5: 499-502 [PMID: 387703]
71. Mendz GL, Mégraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002; 10: 370-375 [PMID: 12160635]
72. Chisholm SA, Owen RJ. Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother 2003; 51: 995-999 [PMID: 12654749]
73. Marais A, Bilardi C, Cantet F, Mendz GL, Mégraud F. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003; 154: 137-144 [PMID: 12648728]
74. Seo JH, Jun JS, Yeom JS, Park JS, Youn HS, Ko GH, Baik SC, Lee WK, Cho MJ, Rhee KH. Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea. Pediatr Int 2013; 55: 332-336 [PMID: 23279258 DOI: 10.1111/ped.12048]
75. Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004; 48: 4843-4847 [PMID: 15561865]
76. Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, Muñoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39: 2677-2680 [PMID: 11427594]
77. Marie MAM. Patterns of Helicobacter pylori resistance to metronidazole, clarithromycin and amoxicillin in Saudi Arabia. J Bacteriol Virol 2008; 38: 173-178 [DOI: 10.4167/ jbv.2008.38.4.173]
78. Loffeld RJ, Werdmuller BF. Changes in Antibiotic Susceptibility of Helicobacter pylori in the Course of Eight Years in the Zaanstreek Region in The Netherlands. Gastroenterol Res Pract 2013; 2013: 625937 [PMID: 23573077 DOI: 10.1155/2013/625937]
79. Elviss NC, Owen RJ, Xerry J, Walker AM, Davies K. Helicobacter pylori antibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother 2004; 54: 435-440 [PMID: 15243025]
80. Hojsak I, Kos T, Dumančić J, Mišak Z, Jadrešin O, Jaklin Kekez A, Lukić Grlić A, Kolaček S. Antibiotic resistance of Helicobacter pylori in pediatric patients--10 years' experience. Eur J Pediatr 2012; 171: 1325-1330 [PMID: 22430353 DOI: 10.1007/s00431-012-1722-8]
81. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010; 19: 409-414 [PMID: 21188333]
82. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007; 25: 1429-1434 [PMID: 17539982]
83. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563 [PMID: 17438314]
84. Berrutti M, Pellicano R, Astegiano M, Smedile A, Saracco G, Morgando A, De Angelis C, Repici A, Fagoonee S, Leone N, Rizzetto M. Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy. Minerva Gastroenterol Dietol 2008; 54: 355-358 [PMID: 19047976]
85. Saracino IM, Zullo A, Holton J, Castelli V, Fiorini G, Zaccaro C, Ridola L, Ricci C, Gatta L, Vaira D. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis 2012; 21: 363-365 [PMID: 23256118]
86. Mollison LC, Stingemore N, Wake RA, Cullen DJ, Mc-Gechie DB. Antibiotic resistance in Helicobacter pylori. Med J Aust 2000; 173: 521-523 [PMID: 11194734]
87. Ahmed D, Brooks H, McConnell M, Barbezat G. Antibiotic resistance in Helicobacter pylori: is it a problem in New Zealand? N Z Med J 2004; 117: U1022 [PMID: 15475992]
88. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
89. Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol 2011; 2: 35-41 [PMID: 21860834 DOI: 10.4291/wjgp. v2.i3.35]
90. Bago J, Halle ZB, Strinić D, Kućisec N, Jandrić D, Bevanda M, Tomić M, Bilić A. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate-vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. Wien Klin Wochenschr 2002; 114: 448-453 [PMID: 12422579]
91. Mégraud F. Surveillance de la résistance de Helicobacter pylori aux antibiotiques. In: Surveillance nationale des ma-ladies infectieuses 1998-2000. St Maurice, France: Institut de Veille Sanitaire, 2003: 327-329
92. Wolle K, Leodolter A, Malfertheiner P, König W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-709 [PMID: 12171304]
93. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999; 43: 511-515 [PMID: 10350380]
94. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, Lopes AI, Ramalho P, Neves BC, Guerreiro AS. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-1031 [PMID: 11102427]
95. Cuchí Burgos E, Forné Bardera M, Quintana Riera S, Lite Lite J, Garau Alemany J. [Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment]. Enferm Infecc Microbiol Clin 2002; 20: 157-160 [PMID: 11996701]
96. Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-2752 [PMID: 10543758]
97. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-545 [PMID: 14567457]
98. Parsons HK, Carter MJ, Sanders DS, Winstanley T, Lobo AJ. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001; 15: 1473-1478 [PMID: 11552921]
99. Teare L, Peters T, Saverymuttu S, Owen R, Tiwari I. Antibiotic resistance in Helicobacter pylori. Lancet 1999; 353: 242 [PMID: 9923909]
100. Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis 2007; 44: 977-980 [PMID: 17342653]
101. Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho 1998; 56: 3096-3099 [PMID: 9883617]
102. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997; 61: 377-392 [PMID: 9293187]
103. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 1995; 39: 107-111 [PMID: 7695290]
104. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-640 [PMID: 17008172]
105. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
106. O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, O'Connor H, McNamara D, Murphy P, O'Morain C. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci 2013; 182: 693-695 [PMID: 23625165]
107. Wueppenhorst N, Stueger HP, Kist M, Glocker EO. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother 2013; 68: 1562-1566 [PMID: 23463210 DOI: 10.1093/jac/dkt061]
108. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low-and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47: 3942-3944 [PMID: 14638505]
109. Monno R, Capolongo C, Giorgio F, Losurdo G, Di Leo A, Ierardi E. An overview of antibiotic phenotypic resistances to Helicobacter pylori (Hp) in Southern Italy: may tigecycline be the "drug of the future?". Madrid: Proceedings European Helicobacter Study Group Meeting, 2013: 12-14 (abstract A156)
110. Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, McMahon B. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 2011; 49: 3638-3643 [PMID: 21813726 DOI: 10.1128/JCM.01067-11]
111. Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol 2011; 48: 261-264 [PMID: 22147131]
112. Ling TK, Leung WK, Lee CC, Ng EK, Yung MY, Chung SS, Sung JJ, Cheng AF. The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001). Helicobacter 2002; 7: 327-328 [PMID: 12390214]
113. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459-461 [PMID: 11266421]
114. Trieber CA, Taylor DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 2002; 184: 2131-2140 [PMID: 11914344]
115. Gerrits MM, de Zoete MR, Arents NL, Kuipers EJ, Kusters JG. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2996-3000 [PMID: 12183259]
116. Pinheiro M, Pereira-Leite C, Arêde M, Nunes C, Caio JM, Moiteiro C, Giner-Casares JJ, Lúcio M, Brezesinski G, Camacho L, Reis S. Evaluation of the structure-activity relationship of rifabutin and analogs: a drug-membrane study. Chemphyschem 2013; 14: 2808-2816 [PMID: 23821530 DOI: 10.1002/cphc.201300262]
117. Heep M, Beck D, Bayerdörffer E, Lehn N. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497-1499 [PMID: 10348780]
118. Fujimura S, Kato S, Kawamura T, Watanabe A. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 2002; 49: 541-543 [PMID: 11864956]
119. Tan Y, Hu Z, Zhao Y, Cai X, Luo C, Zou C, Liu X. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. J Clin Microbiol 2012; 50: 81-85 [PMID: 22075601 DOI: 10.1128/JCM.05092-11]
120. Heep M, Rieger U, Beck D, Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 1075-1077 [PMID: 10722516]
121. World Gastroenterology Organisation. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Clin Gastroenterol 2011; 45: 383-388 [PMID: 21415768 DOI: 10.1097/MCG.0b013e31820fb8f6]
122. Machado RS, Silva MR, Viriato A. Furazolidone, tetracycline and omeprazole: a low-cost alternative for Helicobacter pylori eradication in children. J Pediatr (Rio J) 2008; 84: 160-165 [PMID: 18372934 DOI: 10.2223/JPED.1772]
123. Alarcón T, de la Obra P, Domingo D, García-Campos JA, Díaz-Regañón J, López-Brea M. [In vitro activity of furazolidone and nitrofurantoin in Helicobacter pylori clinical isolates and study of mutation rate]. Rev Esp Quimioter 2005; 18: 313-318 [PMID: 16446791]
124. Boyanova L, Gergova G, Nikolov R, Davidkov L, Kamburov V, Jelev C, Mitov I. Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 2008; 60: 409-415 [PMID: 18248937 DOI: 10.1016/j.diagmicrobio.2007.11.008]
125. Rafeey M, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in Helicobacter pylori isolated in children from Iran. J Infect Chemother 2007; 13: 291-295 [PMID: 17982716]
126. Zullo A, Ierardi E, Hassan C, De Francesco V. Furazolidonebased therapies for Helicobacter pylori infection: a pooleddata analysis. Saudi J Gastroenterol 2012; 18: 11-17 [PMID: 22249086 DOI: 10.4103/1319-3767.91729]
127. De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J Gastrointest Pharmacol Ther 2012; 3: 68-73 [PMID: 22966485 DOI: 10.4292/ wjgpt.v3.i4.68]
128. Ching SS, Sabanathan S, Jenkinson LR. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol 2008; 14: 3855-3860 [PMID: 18609709]
129. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913 [PMID: 21345487 DOI: 10.1016/ S0140-6736(11)60020-2]
130. Songür Y, Senol A, Balkarli A, Baştürk A, Cerçi S. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009; 338: 50-53 [PMID: 19474657 DOI: 10.1097/ MAJ.0b013e31819c7320]
131. Pai CG, Thomas CP, Biswas A, Rao S, Ramnarayan K. Quadruple therapy for initial eradication of Helicobacter pylori in peptic ulcer: comparison with triple therapy. Indian J Gastroenterol 2003; 22: 85-87 [PMID: 12839378]
132. Hong J, Yang HR. Efficacy of Proton Pump Inhibitor-based Triple Therapy and Bismuth-based Quadruple Therapy for Helicobacter pylori Eradication in Korean Children. Pediatr Gastroenterol Hepatol Nutr 2012; 15: 237-242 [PMID: 24010093 DOI: 10.5223/pghn.2012.15.4.237]
133. Veldhuyzen van Zanten S, Chiba N, Barkun A, Fallone C, Farley A, Cockeram A, Dallaire C, Simms L, Nicholls B. A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori. Can J Gastroenterol 2003; 17: 533-538 [PMID: 14532926]
134. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idström JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-144 [PMID: 9398894]
135. Wong BC, Chang FY, Abid S, Abbas Z, Lin BR, Van Rensburg C, Chen PC, Schneider H, Simjee AE, Hamid SS, Seebaran A, Zhang J, Destefano M, Lam SK. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14: 1529-1535 [PMID: 11069326]
136. Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi A, Benajah DA. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study. Clin Res Hepatol Gastroenterol 2013; 37: 416-421 [PMID: 23168228 DOI: 10.1016/j.clinre.2012.10.002]
137. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007; 26: 1537-1542 [PMID: 17903237]
138. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C. Efficacy and safety of rifabutincontaining 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 481-488 [PMID: 16441468]
139. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567 [PMID: 12650788]
140. Rodgers C, van Zanten SV. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol 2007; 21: 295-300 [PMID: 17505565]
141. Mantzaris GJ, Petraki K, Archavlis E, Amberiadis P, Christoforidis P, Kourtessas D, Chiotakakou E, Triantafyllou G. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002; 14: 1237-1243 [PMID: 12439119]
142. Zheng Q, Chen WJ, Lu H, Sun QJ, Xiao SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance. J Dig Dis 2010; 11: 313-318 [PMID: 20883428 DOI: 10.1111/ j.1751-2980.2010.00457.x]
143. Tay CY, Windsor HM, Thirriot F, Lu W, Conway C, Perkins TT, Marshall BJ. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations. Aliment Pharmacol Ther 2012; 36: 1076-1083 [PMID: 23072648 DOI: 10.1111/apt.12089]
144. Nagahara A, Miwa H, Ogawa K, Kurosawa A, Ohkura R, Iida N, Sato N. Addition of metronidazole to rabeprazoleamoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000; 5: 88-93 [PMID: 10849057]
145. Choi C, Lee D, Chon I. Concomitant therapy was more effective than ppi-base triple therapy in Korea: a preliminary report. Helicobacter 2011; 16 (Suppl 1): 136
146. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002; 162: 153-160 [PMID: 11802748]
147. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/ metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3: 54-58 [PMID: 9546119]
148. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-514 [PMID: 21777974 DOI: 10.1016/S0140-6736(11)60825-8]
149. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587 [PMID: 23926315 DOI: 10.1136/bmj.f4587]
150. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129: 1414-1419 [PMID: 16285942]
151. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina M, Ierardi E, Morini S, Vaira D. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005; 21: 1419-1424 [PMID: 15948808]
152. Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol 2013; 69: 1709-1715 [PMID: 23695545 DOI: 10.1007/s00228-013-1524-6]
153. Zegarra Chang A, Bravo Paredes E, Piscoya Rivera A, De Los Ríos Senmache R, Pinto Valdivia JL, Huerta-Mercado Tenorio J. ["Pilot study: sequential therapy in erradicating Helicobacter pylori in the Cayetano Heredia Hospital"]. Rev Gastroenterol Peru 2011; 31: 21-25 [PMID: 21544152]
154. Kim YS, Kim SJ, Yoon JH, Suk KT, Kim JB, Kim DJ, Kim DY, Min HJ, Park SH, Shin WG, Kim KH, Kim HY, Baik GH. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011; 34: 1098-1105 [PMID: 21923713 DOI: 10.1111/j.1365-2036.2011.04843.x]
155. Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, Shang L, Pan XL, Shi RH, Zhang GX. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012; 17: 478-485 [PMID: 23067317 DOI: 10.1111/j.1523-5378.2012.00993.x]
156. Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. Aliment Pharmacol Ther 2013; 37: 1165-1171 [PMID: 23656465 DOI: 10.1111/apt.12329]
157. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D'Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P. Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study. Clin Res Hepatol Gastroenterol 2013; pii: S2210-7401(13)00090-9 [PMID: 23747131 DOI: 10.1016/j.clinre.2013.04.003]
158. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129-134 [PMID: 23121338 DOI: 10.1111/hel.12017]
159. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
160. Molnar B, Szoke D, Ruzsovics A, Tulassay Z. Significantly elevated Helicobacter pylori density and different genotype distribution in erosions as compared with normal gastric biopsy specimen detected by quantitative real-time PCR. Eur J Gastroenterol Hepatol 2008; 20: 305-313 [PMID: 18334874]
161. De Francesco V, Giorgio F, Ierardi E, D'Ercole C, Hassan C, Zullo A. Helicobacter pylori clarithromycin resistance assessment: are gastric antral biopsies sufficient? Gastroenterology Insights 2012; 4: e2
162. van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-326 [PMID: 10673291]
163. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, Russo F, Barone M, Di Leo A, Minenna MF, Stoppino V, Morini S, Panella C, Francavilla A, Ierardi E. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407-414 [PMID: 14871280]
164. Kusters JG, Gerrits MM, Van Strijp JA, Vandenbroucke-Grauls CM. Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun 1997; 65: 3672-3679 [PMID: 9284136]
165. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of highdose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001; 70: 484-492 [PMID: 11719736]
166. Hirschowitz BI, Haber MM. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther 2001; 15: 87-103 [PMID: 11136282]
167. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17: 755-773 [PMID: 14507586]
168. Rosania R, Minenna MF, Giorgio F, Facciorusso A, De Francesco V, Hassan C, Panella C, Ierardi E. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm Allergy Drug Targets 2012; 11: 244-249 [PMID: 22452604]
169. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Effect of different probiotic preparations on antihelicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744-2749 [PMID: 12425542]
170. Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 21: 1263-1272 [PMID: 15882248]
171. Yoon H, Kim N, Kim JY, Park SY, Park JH, Jung HC, Song IS. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011; 26: 44-48 [PMID: 21175792 DOI: 10.1111/j.1440-1746.2010.06477.x]
172. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, De Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 2008; 13: 127-134 [PMID: 18321302 DOI: 10.1111/ j.1523-5378.2008.00593.x]
173. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]